- In March 2023, Perrigo Company plc received final approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for acetaminophen and ibuprofen tablets (250 mg/125 mg). These medications are commonly used to treat Aseptic Necrosis
- In March 2023, AFT Pharmaceuticals gained FDA approval for Combogesic, a combination of acetaminophen and ibuprofen, for the short-term management of mild to moderate acute pain. These drugs are frequently used in the treatment of Aseptic Necrosis
- In August 2021, Dr. Reddy's Laboratories Ltd. reintroduced over-the-counter (OTC) Naproxen Sodium Tablets USP (220 mg), a store-brand equivalent of Aleve, in the U.S. market following approval by the FDA
- In April 2021, ECI Pharmaceuticals, LLC partnered with AiPing Pharmaceuticals, Inc. to manage the sales, marketing, and distribution of Ibuprofen tablets (400 mg, 600 mg, and 800 mg) and Folic Acid tablets (1 mg) in the U.S
- In December 2020, Novartis AG received European Commission (EC) approval for Leqvio (inclisiran), a first-in-class small interfering RNA (siRNA) therapy for treating adults with hypercholesterolemia or mixed dyslipidemia, providing sustained LDL-C reduction in patients with atherosclerotic cardiovascular disease (ASCVD)
